Abstract:Objective: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). Methods: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases. The follow-up ended in June 2016 or the death of the patient. The survival was from the operation to the death of the patient or the end of follow-up. Results: There were a total of 24 cases with gastic HAS, accounting for 1.03%(24/2 326) of the total number of patients with gastric cancer diagnosed at the same time in our center. There were 19 males and 5 females, the ratio of male to female was 3.8:1.0, the mean age of the patients was 55.9 (31 to 72) years, and 2 of them had liver metastasis. The first symptom in 50% (12/24) patients was epigastric pain, in 25%(6/24) was abdominal distension with vomiting, and the rest included dysphagia (12.5%, 3/24), hematemesis (8.3%, 2/24) and melena (4.2%, 1/24). Preoperative serum levels of AFP and CEA were elevated in 10 (41.7%) and 5 patients (20.8%) respectively. All the patients underwent surgical treatment, including 23 cases with D2 radical resection of gastric cancer and R0 resection, and the other of palliative gastrojejunostomy. Lesions of HAS located in gastric antrum in 11 cases (45.8%), in cardia in 7 cases (29.2%), and in gastric body in 6 cases (25%). Tumor maximum diameter of 10 cases was larger than 5 cm, and the average diameter was 5.7(1.0 to 12.0) cm. Postoperative pathological TNM staging: stage I(b was in 1 cases, stage II( in 7 cases, stage III( in 14 cases, stage IIII( in 2 cases; lymph node metastasis in stage N1-3 in 20 cases (83.3%). Poorly-differentiated tumors were found in 21 cases (87.5%), and no well-differentiated tumors were found. There were 11 cases (45.8%) with formation of intravascular tumor thrombi. In immunohistochemistry, AFP positive expression was found in 11 cases(45.8%). Seventeen HAS cases (70.8%, 17/24) received postoperative SOX(oxaliplatin + S-1) or XELOX (oxaliplatin + capecitabine) as adjuvant chemotherapy, 5 cases postoperative immune therapy, and 2 cases postoperative traditional Chinese medicine. All the patients were followed up for 0.7 to 42.0 months (median 8 months). A total of 9 patients died, of whom, 1 case underwent gastrojejunostomy because of liver and peritoneal metastasis before operation, and died 20 days after surgery; 4 cases died of multiple liver metastases after 1.5 to 12.0 months with survival of 3 to 18 months; 3 cases presented local recurrence after 2 to 17 months with survival of 6 to 22 months; 1 cases had peritoneal metastasis after 12 month with survival of 26 months. Conclusions: HAS is a rare type of gastric cancer with poor prognosis. The diagnosis is mainly based on histopathology, and radical resection is the mainstay treatment.

Clinicopathological and Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach.

Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes.

[Clinical Characteristics, Diagnosis and Treatment of Hepatoid Adenocarcinoma of the Stomach].

Clinicopathologic characteristics and prognosis of Hepatoid Adenocarcinoma of the stomach: a retrospective study

Clinicopathological Features and Prognostic Factors in Gastric Hepatoid Adenocarcinoma

Clinicopathological Characteristics and Prognosis of Hepatoid Adenocarcinoma of the Stomach: Evaluation of a Pooled Case Series

Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics

The clinicopathological characteristics and prognosis of 30 patients with hepatoid ade-nocarcinoma of stomach

Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach.

Immunohistochemical Characteristics and Potential Therapeutic Regimens of Hepatoid Adenocarcinoma of the Stomach: a Study of 139 Cases.

An Analysis of Clinicopathological Features and Prognosis by Comparing Hepatoid Adenocarcinoma of the Stomach with Afp-Producing Gastric Cancer

Emphasis on the Clinical Relationship Between Alpha-Fetoprotein and Hepatoid Adenocarcinoma of the Stomach: a Retrospective Study

Genomic Profiling and the Impact of MUC19 Mutation in Hepatoid Adenocarcinoma of the Stomach

[Clinicopathologic characteristics and prognosis of gastric hepatoid adenocarcinoma]

Genomic Alterations and Clinical Correlations of Chinese Patients with Hepatoid Adenocarcinoma of the Stomach/alpha-Fetoprotein Gastric Cancer.

Carcinosarcoma of the Stomach with Alpha-Fetoprotein-producing Hepatoid Adenocarcinoma: an Unexpected Combination of Two Rare Subtypes of Gastric Cancer in One Tumor

Hepatoid adenocarcinoma in the peritoneal cavity: Two case reports.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Analysis of Enhanced CT Imaging Signs and Clinicopathological Prognostic Factors in Hepatoid Adenocarcinoma of Stomach Patients with Radical Surgery: a Retrospective Study.

Immunohistochemical and pathological analysis of Hepatoid adenocarcinoma of the stomach: 1 case report

Hepatoid Adenocarcinoma of the Stomach: a Unique Subgroup with Distinct Clinicopathological and Molecular Features